SCHEDULE: AIGH Capital Management and Orin Hirschman Report 4.9% Stake in Cellectar Biosciences

AIGH Capital Management and Orin Hirschman jointly filed a Schedule 13G, disclosing a 4.9% beneficial ownership stake in Cellectar Biosciences, Inc. as of December 31, 2024.

Summary

• A Schedule 13G filing reveals that AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman collectively hold 2,022,221 shares of Cellectar Biosciences, Inc.
• This represents a 4.9% ownership stake in the company's common stock.
• The reported holdings include 2,022,221 warrants to purchase common shares.
• An additional 2,180,067 warrants are excluded due to beneficial ownership limitations on exercise.
• The filing indicates that the shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: The document is a routine filing indicating a significant but not controlling stake. It is neutral to slightly positive as it shows investor interest.

Positives

• The filing indicates that the shares were acquired in the ordinary course of business.
• The filing explicitly states that the shares are not held for the purpose of influencing control of the issuer.

Risks

• The filing indicates that a significant number of warrants are not currently exercisable due to beneficial ownership limitations, which could impact future share dilution.

Industry Context

This filing is a standard disclosure for investors holding more than 5% of a company's stock, or in this case, just under 5% due to warrant limitations. It provides transparency into the ownership structure of Cellectar Biosciences.

Comparison to Industry Standards

• Schedule 13G filings are a common practice for investors who acquire a significant stake in a publicly traded company.
• The 4.9% ownership is below the 5% threshold that would trigger a more detailed Schedule 13D filing, which is required for investors seeking to influence control.
• The exclusion of warrants due to ownership limitations is a standard practice to avoid exceeding ownership thresholds.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding the ownership structure of the company.
• The filing may have a minor positive impact on investor confidence due to the disclosure of a significant investor.

Key Dates

Keywords

Cellectar Biosciences, AIGH Capital Management, Orin Hirschman, Schedule 13G, Beneficial Ownership, Warrants, Investment, Shareholding